Edition:
United States

Neogenomics Inc (NEO.OQ)

NEO.OQ on NASDAQ Stock Exchange Capital Market

7.38USD
26 May 2017
Change (% chg)

$-0.17 (-2.25%)
Prev Close
$7.55
Open
$7.50
Day's High
$7.51
Day's Low
$7.33
Volume
43,571
Avg. Vol
93,909
52-wk High
$9.87
52-wk Low
$6.92

Latest Key Developments (Source: Significant Developments)

NeoGenomics sees Q2 2017 adjusted earnings per share $0.03-$0.04
Wednesday, 26 Apr 2017 07:00am EDT 

April 26 (Reuters) - NeoGenomics Inc :Neogenomics reports 15% volume growth and 10% reduction in average cost per test in the first quarter of 2017.Q1 adjusted earnings per share $0.03.Sees q2 2017 adjusted earnings per share $0.03 to $0.04.Sees q2 2017 loss per share $0.03 to $0.04.Sees q2 2017 revenue $62 million to $64 million.Q1 revenue $61.7 million versus i/b/e/s view $61.6 million.Q1 gaap loss per share $0.04.Q1 earnings per share view $0.03 -- Thomson Reuters I/B/E/S.Neogenomics inc sees full year consolidated 2017 revenue to be $255 - $265 million.Neogenomics inc sees 2017 gaap diluted eps to be a loss of $0.10 - loss of $0.06 per share.Neogenomics inc - expects adjusted ebitda to be $39 - $46 million for 2017.Neogenomics inc sees adjusted diluted eps to be $0.17 - $0.21 per share for 2017.Fy2017 earnings per share view $0.19, revenue view $264.6 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $0.04, revenue view $66.0 million -- Thomson Reuters I/B/E/S.  Full Article

NeoGenomics and Definiens to develop novel assays for clinical trials & clinical testing
Monday, 13 Mar 2017 07:00am EDT 

NeoGenomics Inc - : NeoGenomics and Definiens enter into agreement to develop novel assays for clinical trials & clinical testing . Co, definiens expanded alliance to develop and automate analysis of new biomarker assays for clinical trials, routine clinical testing .definiens to provide automated quantitative biomarker solutions to support neogenomics' immunohistochemistry services.  Full Article

NeoGenomics Q4 GAAP loss per share $0.18
Wednesday, 22 Feb 2017 07:00am EST 

NeoGenomics Inc : NeoGenomics reports 122% revenue growth to $60.5 million and 11% reduction in average cost per test in the fourth quarter of 2016 . Q4 adjusted earnings per share $0.05 . Q4 GAAP loss per share $0.18 . Q4 revenue $60.5 million versus I/B/E/S view $61.8 million . Q4 earnings per share view $0.03 -- Thomson Reuters I/B/E/S . NeoGenomics Inc - company expects full year consolidated 2017 revenue to be in range of $260 - $275 million . NeoGenomics Inc -sees FY adjusted EBITDA to be in range of $42 - $50 million . NeoGenomics Inc - sees FY adjusted diluted EPS to be in range of $0.17 - $0.22 per share .NeoGenomics Inc - sees FY GAAP diluted EPS to be a loss of ($0.10) - ($0.05) per share.  Full Article

Neogenomics Inc, some units and Neogenomics Laboratories enter credit agreement - SEC filing
Tuesday, 27 Dec 2016 05:44pm EST 

Neogenomics Inc : Neogenomics Inc - on December 22, 2016, Neogenomics Laboratories Inc and co and units entered into a credit agreement - SEC filing . Neogenomics Inc - credit agreement provides incremental facility capacity of $50 million - SEC filing . Neogenomics Inc says credit agreement provides for a $75 million revolving credit facility and a $75 million term loan facility .Neogenomics Inc - any principal outstanding under revolving credit facility is due and payable on December 21, 2021.  Full Article

NeoGenomics sees FY 2016 GAAP loss of $0.30-$0.28/share
Thursday, 22 Dec 2016 09:51am EST 

NeoGenomics Inc : NeoGenomics also revised its guidance for fiscal year 2016 . Sees FY 2016 revenue $244 mln to $246 mln . For FY 2016 company now expects GAAP diluted EPS to be a loss of $0.30 - $0.28 per share . FY 2016 earnings per share view $0.14, revenue view $247.6 mln -- Thomson Reuters I/B/E/S . FY 2016 adjusted diluted EPS to be approximately $0.13 - $0.15 per share . Expect only minimal increases in 2017 interest expense despite higher principal outstanding . Have $52 mln available under revolving credit facility to pursue strategic opportunities . NeoGenomics closes $150 mln senior credit facility .Facility also reduces our weighted average cost of senior debt capital to roughly half previous level.  Full Article

NeoGenomics Q2 adjusted earnings per share $0.04
Tuesday, 26 Jul 2016 07:00am EDT 

Neogenomics Inc : Neogenomics reports 159% revenue growth to $63.1 million and strong gains in profitability in the second quarter of 2016 . Q2 adjusted earnings per share $0.04 . Q2 loss per share $0.07 . Q2 revenue $63.1 million versus i/b/e/s view $61.1 million . Q2 earnings per share view $0.03 -- Thomson Reuters I/B/E/S .Neogenomics inc says reiterated guidance for fiscal year 2016.  Full Article

Neogenomics files for stock shelf of up to $200 mln
Friday, 17 Jun 2016 04:05pm EDT 

Neogenomics Inc :Files for stock shelf of up to $200 million - SEC filing.  Full Article

Neogenomics Inc gives FY 2016 guidance
Tuesday, 1 Mar 2016 07:00am EST 

Neogenomics Inc:Expects FY 2016 revenue to be in the range of $240 - $250 million.Expects FY 2016 adjusted EBITDA to be in the range of $33 - $38 million.Expects FY 2016 adjusted net income to be in the range of $7 - $12 million, and adjusted diluted EPS to be in the range of $0.07 - $0.12 per share.  Full Article

NeoGenomics Inc completes acquisition of Clarient Inc
Wednesday, 30 Dec 2015 04:10pm EST 

NeoGenomics Inc:Announced that it has completed the acquisition of Clarient, Inc. and its wholly-owned subsidiary Clarient Diagnostic Services, Inc.  Full Article

NeoGenomics Inc sees fY 2015 revenue guidance near low end of prior range
Thursday, 29 Oct 2015 07:00am EDT 

NeoGenomics Inc:Expects full year 2015 revenue to be near the lower end of previous full-year revenue guidance of $100 - $103 million.  Full Article

More From Around the Web

BRIEF-NeoGenomics sees Q2 2017 adjusted earnings per share $0.03-$0.04

* Neogenomics reports 15% volume growth and 10% reduction in average cost per test in the first quarter of 2017